Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

ImmunoChemistry Technologies Changes Ownership

By Drug Discovery Trends Editor | December 6, 2013

ImmunoChemistry Technologies (ICT), a Minnesota-based biotechnology company that supplies unique biochemical laboratory reagents and assay tests to medical researchers, has changed ownership. Now majority women-owned, ICT develops new products to help researchers discover new treatments and drugs for cancer and other diseases affecting both animals and humans.
 
The privately held company is now majority owned by Sally Hed, vice president of marketing and operations, and Carol Lee, secretary and board member. Brian W. Lee, PhD, president and co-founder, owns one-third of the company and is in charge of ICT’s research and development. ICT has consistently achieved double-digit growth thanks to a solid customer base with an international distributor network serving labs all over the world.
 
“We’re now poised for new product growth,” Lee said. “We’re focused on getting new products out that are pertinent to the scientific marketplace and enable researchers to do their jobs better.”
 
ICT’s proprietary products are providing researchers the tools to monitor the effectiveness of cancer treatments. For example, researchers can now determine if the treatment is killing the cancer cells in laboratory animals. Eventually when the product is approved for use in humans, they will be able to tell if the patient is getting the correct dosage or if another treatment or drug would be more effective.
 
“Currently, it may take several days to a week for doctors to gauge the effectiveness of a particular chemotherapy regimen in their cancer patients,” Hed said. “One day, that answer may be made available to doctors in 48 hours or less.”
 
ICT makes several proprietary reagents as well as a wide array of assays that enable scientific researchers to detect apoptosis or programmed cell death, and caspases, the enzymes involved in apoptosis. ICT also makes blocking buffers, wash buffers and other solutions for researchers who are developing ELISA tests. ELISA, or enzyme-linked immunosorbent assay, revolutionized immunology research and product development 30 years ago. Commonly used in medical research labs all over the world, ELISA still enables researchers to detect and quantify specific proteins present in biological fluids.
 
ICT received its first patent in 2012 for the use of its Flivo apoptosis detection technology to detect early stage eye disease such as macular degeneration before any vision loss has occurred. This proprietary technology can be used to detect cell death or apoptosis in living subjects because the detection tracers are non-toxic, cell-permeant reagents. Flivo technology is designed to enable researchers to develop more efficient and cost-effective ways to evaluate and screen chemotherapy drugs.
 
ICT’s customers are established and published biomedical research scientists at leading universities such as Harvard, Yale, Vanderbilt, and the University of Minnesota. Researchers at prominent cancer research centers such as Fred Hutchinson Cancer Research Center, Moffitt Cancer Center, Howard Hughes Medical Institute, and MD Anderson Cancer Center also use ICT’s products to investigate and evaluate the biochemical basis for new cancer treatments.
 
 
Date: December 3, 2013
Source: ImmunoChemistry Technologies
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE